Clinical Advisory Board
Chris Bowden, M.D.
- Chief Medical Officer, Remix Therapeutics
Randi Isaacs, M.D.
- Chief Medical Officer, Werewolf Therapeutics (NASDAQ: HOWL)
Beni Wolf, M.D., Ph.D.
- Chief Medical Officer, Relay Therapeutics (NASDAQ: RLAY)
Hagop Youssoufian, M.D.
- Former faculty member at Harvard Medical School and Baylor College of Medicine
- Former CMO of ImClone-Lilly and other biotechnology companies
- Member, American Society of Clinical Investigation
Scientific Advisory Board
Ken Anderson, M.D.
- Kraft Family Professor of Medicine, Harvard Medical School
- Director of the Jerome Lipper Multiple Myeloma Center and Lebow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute
Scott Armstrong, M.D., Ph.D.
- Chairman of the Department of Pediatric Oncology, Dana-Farber Cancer Institute
- Associate Chief, Department of Hematology/Oncology, Boston Children’s Hospital
- David G. Nathan Professor of Pediatrics, Harvard Medical School
Ryan B. Corcoran, M.D., Ph.D.
- Director of the Gastrointestinal Cancer Center Program
- Scientific Director of the Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center
Nathanael Gray, Ph.D.
- Faculty Lead, Medicinal Chemistry Professor, Chemical and Systems Biology, Stanford University
- Stanford Cancer Institute Director of Cancer Drug Discovery
Christopher Kirk, Ph.D.
- President and Chief Scientific Officer, Kezar Life Sciences (NASDAQ : KZR)
Ross Levine, M.D.
- Attending Physician on the Leukemia Service, Department of Medicine, the Laurence Joseph Dineen Chair in Leukemia Research
- Professor of Medicine, Weill Cornell Medical College
- Director of the MSK Center for Hematologic Malignancies
